Health
Gendered care for young people is “weak”
The medical evidence underpinning gender care for adolescents is “remarkably weak” and offers little clarity on long-term outcomes, according to a state-funded NHS England study.
Pfizer RSV injection met targets in a study of high-risk adults under 60 years of age
Pfizer said Tuesday that its respiratory syncytial virus (RSV) vaccine, Abrisvo, is well tolerated and induces an immune response in high-risk adults under the age
US FDA again refuses to approve Supernus combination for Parkinson’s
Supernus Pharmaceuticals said the US FDA has refused to approve a drug and device combination to treat Parkinson’s disease’s movement-related symptoms, sending its shares down
Dengue epidemic risk rises in Argentina
Mosquitoes are hatching earlier in Argentina and reaching colder regions than before, as rising temperatures drive the country’s worst dengue outbreak. So far in the
Novo Nordisk parent company resubmits US bid for Catalent deal
The parent company of Wegovy maker Novo Nordisk has reapplied to the US Federal Trade Commission for approval of a $16.5bn deal to buy manufacturing
Geneos cancer vaccine shrinks liver tumours in small study
Nearly a third of patients with advanced liver cancer who received a personalised vaccine developed by Geneos Therapeutics along with an immunotherapy drug in a
Synchron is preparing a large-scale brain implant trial
Synchron is preparing to recruit patients for a large-scale clinical trial needed to gain commercial approval for its device, the company’s chief executive told Reuters.
US FDA approves expanded use of J&J cancer cell therapy
The US Food and Drug Administration has authorised the expanded use of Johnson & Johnson and Legend Biotech’s Carvicti cell therapy as an early treatment
Bristol Myers’ schizophrenia drug reduces symptoms without weight gain
Bristol Myers Squibb said Saturday that data from late-stage studies of its experimental schizophrenia drug showed it helps reduce symptoms of the disorder without the
The US FDA has approved AstraZeneca’s drug for the treatment of solid tumours
The US Food and Drug Administration has granted accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca’s drug to treat patients with solid